The Impact of Folic Acid and Vitamin B12 Supplementation on Blood Pressure and Arterial Stiffness in Subjects with Subnormal Micronutrient Intake

2008 ◽  
Vol 17 ◽  
pp. S84 ◽  
Author(s):  
K.S. Woo ◽  
P. Chook ◽  
L.L.T. Chan ◽  
D.S. Celermajer
2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Sadaf Oliai Araghi ◽  
Jessica C Kiefte-de Jong ◽  
Suzanne van Dijk ◽  
Natasja van Schoor ◽  
Lisette CPGM de Groot ◽  
...  

Abstract Objectives To investigate the possible effects of the intervention with folic acid and vitamin B12 supplementation on fracture and cardiovascular disease risk: 5–7 years after the end of the intervention period of 2–3 years. Methods Extended follow-up of B-PROOF trial, a multi-center, double-blind randomized placebo-controlled trial designed to assess the effect of 2–3 years daily supplementation with folic acid (400 µg) and vitamin-B12 (500 µg) versus placebo on fracture incidence. Fracture and cardiovascular outcomes were assessed by follow-up questionnaire. Fracture incidence (and a part of cardiovascular disease incidence) was verified by general practitioners (GPs). Results A total of 1298 individuals participated in the second follow-up round. Median age at baseline was 71.0 years [68.0–76.0] for both groups (n = 662 in the treatment group and n = 636 in the placebo group). No effect of the intervention on first osteoporotic fracture and other fracture risk after a follow up of 5–7 years was observed (HR: 0.99, 95% CI: 0.62; 1.59 and HR: 0.77; 95% CI: 0.50; 1.19, respectively) and also not for cardiovascular- or cerebrovascular disease (OR: 1.14; 95%CI: 0.74–1.74 and OR: 1.01; 95%CI: 0.76–1.33, respectively). Significant interaction for total homocysteine level was observed for osteoporotic- and any fracture (P = 0.10 and 0.06 resp.), which indicated a significantly lower risk of fracture in the intervention group with higher total homocysteine level. Conclusions This study does not support a prolonged effect of supplementation of folic acid and vitamin B12 on fracture risk, or on cardiovascular disease in older individuals with elevated homocysteine concentration. However, B-vitamin supplementation may be beneficial in reducing fractures in individuals with higher total homocysteine levels. Funding Sources The initial B-PROOF study has received funding so far by The Netherlands Organization for Health Research and Development (ZonMw), the Hague; unrestricted grant from NZO (Dutch Dairy Association), Zoetermeer; Orthica, Almere; NCHA (Netherlands Consortium Healthy Ageing) Leiden/Rotterdam; Ministry of Economic Affairs, Agriculture and Innovationn, the Hague; Wageningen University, Wageningen; VUmc, Amsterdam; Erasmus Medical Center, Rotterdam. Supporting Tables, Images and/or Graphs


2016 ◽  
Vol 15 (1) ◽  
Author(s):  
Ryotaro Bouchi ◽  
Norihiko Ohara ◽  
Masahiro Asakawa ◽  
Yujiro Nakano ◽  
Takato Takeuchi ◽  
...  

Kardiologiia ◽  
2019 ◽  
Vol 59 (3) ◽  
pp. 18-26 ◽  
Author(s):  
E. V. Borisova ◽  
A. I. Kochetkov ◽  
O. D. Ostroumova

Objective: to investigate the impact of indapamide / perindopril single-pill combination (I / P SPC) on arterial stiffness parameters, blood pressure (BP) level and BP variability (BPV) in middle-aged patients with stage II grade 1–2 essential arterial hypertension (EAH). Materials and methods. We retrospectively formed a group of patients with stage II grade 1–2 EAH who had not previously received regular antihypertensive therapy (AHT) (n=52, mean age 52.9±6.0 years). All patients were treated with I / P SPC and all of them achieved target office BP level (less than 140 / 90 mm Hg). After 12 weeks of follow-up (from the time of reaching the target BP) assessment of AHT effectiveness (general clinical data, ambulatory blood pressure monitoring [ABPM], volume sphygmography, echocardiography), and vascular stiffness evaluation were performed.Results. At the end of follow-up office systolic BP (SBP), diastolic BP (DBP), pulse BP, day-time, night-time and 24‑hour SBP and DBP significantly (p<0.001 for all) decreased. According to the ABPM data day-time, nighttime, and 24‑hour systolic BPV significantly decreased (p=0.029, p=0.006 and p<0.001, respectively); day-time and 24‑hour diastolic BPV also significantly decreased (p=0.001 and p<0.001, respectively). Day-night standard deviation (SDdn) significantly decreased too (p=0.002 and p<0.001, respectively). Volumetric sphygmography showed significant decrease of right cardio-ankle vascular index (CAVI) (from 8.20±1.29 to 7.58±1.44, p=0.001) and of left CAVI (from 8.13±1.40 to 7.46±1.43, p<0.001), as well as reduction of the number o f patients with a right- and / or left-CAVI >9.0 (from 32.7 to 11.5 %, p=0.018). According to assessment of arterial stiffness using the Vasotens24 software package, the arterial stiffness index (ASI) significantly (p<0.001) decreased from 153.5±29.9 to 138.3±20.0 (by –9.2±13.1 %). Transthoracic echocardiography data demonstrated significant decrease (p<0.001) in effective arterial elastance (from 1.82±0.43 to 1.58±0.36 mm Hg; by –11.85±16.29 %) and significant (p<0.001) increase in the arterial compliance – from 1.27±0.34 to 1.54±0.38 mm Hg / ml (+26.95±38.06 %).Conclusion. In AHT naive patients 40–65 years old with stage II grade 1–2 EAH therapy with I / P SPC provided effective 24‑hour BP control, reduced BPV and improved arterial stiffness parameters. 


Author(s):  
Sadaf Oliai Araghi ◽  
Jessica C. Kiefte-de Jong ◽  
Suzanne C. van Dijk ◽  
Karin M.A. Swart ◽  
Kim J. Ploegmakers ◽  
...  

2012 ◽  
Vol 87 (Suppl_1) ◽  
pp. 504-504 ◽  
Author(s):  
Annie Gagnon ◽  
Marc-André Sirard ◽  
François Richard ◽  
Jean-Paul Laforest

2014 ◽  
Vol 97 (4) ◽  
pp. 2346-2354 ◽  
Author(s):  
M. Duplessis ◽  
C.L. Girard ◽  
D.E. Santschi ◽  
J.-P. Laforest ◽  
J. Durocher ◽  
...  

2014 ◽  
Vol 153 ◽  
pp. S80 ◽  
Author(s):  
Joshua Roffman ◽  
Steven J. Lamberti ◽  
Eric Achtyes ◽  
Eric A. Macklin ◽  
Gail C. Galendez ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document